Can We Prevent Congenital Infection by Cytomegalovirus?

Area of Science:

• Virology
• Immunology
• Maternal-Fetal Medicine

Background:

• Congenital Cytomegalovirus (CMV) infection is the most common cause of congenital abnormalities.
• Despite extensive efforts over 50 years, a licensed prophylactic vaccine for CMV remains unavailable.
• Existing vaccine development has faced significant challenges in achieving efficacy.

Purpose of the Study:

• To review the current landscape of Cytomegalovirus (CMV) vaccine development.
• To highlight the potential of modern vaccine platforms for CMV prophylaxis.
• To discuss the prospects for an effective vaccine against congenital CMV infections.

Main Methods:

• Review of historical and contemporary vaccine development strategies for CMV.
• Analysis of emerging vaccine technologies, including mRNA and vector-based platforms.
• Examination of clinical trial data and preclinical research findings.

Main Results:

• Congenital CMV remains a significant public health concern due to its high prevalence and associated morbidities.
• Previous vaccine candidates have shown limited success in large-scale trials.
• Modern vaccine platforms demonstrate promising immunogenicity and potential efficacy in preclinical and early clinical studies.

Conclusions:

• The development of a CMV vaccine is crucial for preventing congenital infections and their sequelae.
• Advanced vaccine technologies offer a renewed opportunity to achieve a safe and effective CMV prophylactic vaccine.
• Continued research and investment are essential to overcome remaining hurdles in CMV vaccine licensure.